Biocentriq® Announces The Successful Completion Of $29.2M Series A Further Strengthening Cell Therapy Contract Development And Manufacturing Services
Biocentriq® Announces The Successful Completion Of $29.2M Series A Further Strengthening Cell Therapy Contract Development And Manufacturing Services
01/03/24, 12:22 PM
Location
newarkMoney raised
$29.2 million
Industry
biotechnology research
Round Type
series a
BioCentriq®, a global cell-based therapy Contract Development and Manufacturing Organization (CDMO), proudly announces the successful completion of its latest round of fundraising, securing $29.2M in capital investment. The funding round marks a significant milestone in BioCentriq's mission to accelerate delivery of innovative cell therapies by translating, optimizing, and scaling processes for GMP manufacture.
Company Info
Location
newark, new jersey, united states
Additional Info
BioCentriq is an established, highly collaborative, global cell therapy CDMO. The company has been successfully manufacturing drug products for use in human clinical trials since 2022. In June of 2023, BioCentriq launched its LEAPTM Advanced Therapy Platform which helps cell therapy developers move from contract to clinic in as short as six months. With industry recognized scientists, engineers, analysts, and manufacturing specialists, established quality systems and modern infrastructure, BioCentriq is a proven strategic partner for the development and manufacturing of both autologous and allogeneic cell therapy products. The company was purchased by GC of South Korea for $73M in May 2022. On behalf of McKinsey, BioCentriq operates the only Innovation & Learning Center designed to explore the application of industry 4.0, digital and lean manufacturing disciplines to life sciences. Visit www.biocentriq.com to learn more.